Imatinib Krka D.D. (Imatinib)

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways and is indicated for several approved oncologic conditions.

• Chronic myeloid leukemia (CML): provides disease control by inhibiting BCR‑ABL signaling.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): facilitates remission through targeted kinase blockade.
• Gastrointestinal stromal tumor (GIST): suppresses tumor growth by blocking c‑KIT and PDGFR activity.

• Imatinib selectively inhibits the ATP‑binding sites of BCR‑ABL, c‑KIT and platelet‑derived growth factor receptors (PDGFR). By preventing phosphorylation of these tyrosine kinases, it blocks downstream proliferative and survival signaling pathways in malignant cells, leading to reduced tumor cell growth and induction of apoptosis.

Adverse reactions to Imatinib may vary in frequency and severity.

Common Side Effects

• Nausea
• Edema (peripheral swelling)
• Muscle cramps or pain
• Fatigue or weakness
• Diarrhea
• Rash or skin irritation

Serious or Rare Side Effects

• Hepatotoxicity (elevated liver enzymes, hepatitis)
• Severe neutropenia or leukopenia
• Cardiac failure or reduced left‑ventricular function
• Pulmonary arterial hypertension
• Severe skin reactions such as Stevens‑Johnson syndrome
• Tumor lysis syndrome

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

• Blood counts monitoring: perform complete blood count before treatment and periodically during therapy.
• Liver function assessment: check hepatic enzymes at baseline and during treatment.
• Cardiac evaluation: assess cardiac status in patients with pre‑existing heart disease.
• Hypersensitivity caution: discontinue if signs of severe allergic reaction appear.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Store at room temperature: keep in the original container, protect from moisture and light.

Imatinib may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Imatinib exposure.
• Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels.
• Concomitant use with other BCR‑ABL inhibitors: risk of overlapping toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: Imatinib can enhance anticoagulant effect; monitor INR.
• Diuretics (e.g., furosemide): may increase risk of fluid retention.
• QT‑prolonging agents (e.g., quinidine): monitor cardiac rhythm.